Treatment of diabetic nephropathy with Tripterygium wilfordii Hook F extract: a prospective, randomized, controlled clinical trial

BACKGROUND: Diabetic nephropathy (DN) is the most common cause of end-stage renal failure. Although angiotensin II receptor blockers (ARBs) can be used to attenuate proteinuria in DN patients, their efficacy remains limited. This clinical trial aimed to evaluate the efficacy of Tripterygium wilfordi...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Ge, Yongchun, Xie, Honglang, Li, Shijun, Jin, Bo, Hou, Jinhua, Zhang, Haitao, Shi, Mingjun, Liu, Zhihong
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3670993/
https://ncbi.nlm.nih.gov/pubmed/23725518
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-134
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky